1. they Wouldn't be planning the Phase III if there are any...

1. they Wouldn't be planning the Phase III if there are any issues with the Phase II. reading between the lines Phase II is going well, without saying so.
2. Phase II is basically on-track per disclosed timelines, it might not be wrapped up by end of next week (by end of Q3), id say another 6-8 weeks for results. This is the readthrough of the Covid commentary etc. This is quite impressive given the issue Covid surely has had on conducting the trial.

3. The Phase III is starting very soon, not sure if the timeline will be similar to Phase II (16 weeks + 4 week washout), if so we are talking Phase 3 results in maybe July next year? Longer trial will obviously push that out.

4. Does successful phase II pave the way straight to phase III for other targeted neuro disorders? I would think so, so turnaround on treatment for MS, and other designations will be much quicker than this ASD trial as the safety piece will have been ticked off.., Anyone has a different view would be interested?

5. The Mente Device - I would like to see some more news on this, another investment I have is not dissimilar to this (But I actually think mente is better/ more clinical) a. I.E I believe the NTI valuation could be supported by Mente alone) The Coy has done a poor job re execution/ commercialising the device and since moved to Cannabis (which I think is very complimentary and why I am ultimately invested)